NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
Sutro Biopharma Announces Virtual Deep Dive Research Forum: Next-Gen Innovations in ADCs
SOUTH SAN FRANCISCO, Calif., July 12, 2022 – Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will host a...
Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)
- iADCs are a next-generation modality for treating cancer and designed to boost anti-cancer activity, offering potential new options for patients who do not respond to existing cancer immunotherapies - - Sutro will receive an upfront payment of US$90 million to...
22nd Annual Federation of Clinical Immunology Societies (FOCIS) Meeting 2022– Abstract and Poster Presentation
Th42 - Next-generation Immunostimulatory Antibody-drug Conjugate (iADC) Combines Direct Tumor Killing and Innate Immune Stimulation to Provide Protective Anti-Tumor Immunity Presenting Author:Kristin Bedard, PhDVP DiscoverySutro BiopharmaSouth San Francisco,...
JMP Securities Life Sciences Conference – Presentation
Jefferies Healthcare Conference 2022 – Presentation
2022 ASCO Annual Meeting – Abstract
Abstract Number TPS5622 STRO-002-GM2: A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination with Bevacizumab in Patients With Advanced Epithelial Ovarian Cancer...
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., June 3, 2022 – Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create...
Bill Newell, CEO Interviewed by Dr. Michelle McMurry-Heath on I Am Bio Podcast, Episode 73 – “Investors Become Goldilocks in a Bear Market”
Episode Summary Current market trends have put investors in a “flight-to-safety” mentality, especially when it comes to biotech companies. What does this mean for getting biotech innovations to the marketplace? This episode explores the daunting challenge of raising...
Sutro Biopharma Participated in a Clinical Trial, “Egg-Derived Anti-SARS-CoV-2 Immunoglobulin Y (IgY) With Broad Variant Activity as Intranasal Prophylaxis Against COVID-19” Published by Frontiers in Immunology
Clinical Trial Article Egg-Derived Anti-SARS-CoV-2 Immunoglobulin Y (IgY) With Broad Variant Activity as Intranasal Prophylaxis Against COVID-19 https://www.frontiersin.org/articles/10.3389/fimmu.2022.899617/full Frontiers in Immunology Published: 01 June 2022
Sutro Biopharma to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., June 2, 2022 – Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create...
